Following feedback from the FDA regarding a Phase 3 registration pathway Viking has decided that further development of VK5211 in hip fracture too challenging. No new clinical studies to be initiated for other indications without a partner. discussions with potential collaborators ongoing. (2019)
Following suggestions from the FDA relating to a Part three registration pathway Viking has determined that additional growth of VK5211 in hip fracture too difficult. No new medical research to be initiated for different indications with no companion. discussions with potential collaborators ongoing. (2019)

By admin

2 thoughts on “Following suggestions from the FDA relating to a Part three registration pathway Viking has determined that additional growth of VK5211 in hip fracture too difficult. No new medical research to be initiated for different indications with no companion. discussions with potential collaborators ongoing. (2019)”

Leave a Reply

Your email address will not be published. Required fields are marked *